|
1
|
Taylor GP and Matsuoka M: Natural history
of adult T-cell leukemia/lymphoma and approaches to therapy.
Oncogene. 24:6047–6057. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sharma VM, Draheim KM and Kelliher MA: The
Notch1/c-Myc pathway in T cell leukemia. Cell Cycle. 6:927–930.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weng AP, Millholland JM, Yashiro-Ohtani Y,
Arcangeli ML, Lau A, Wai C, Del Bianco C, Rodriguez CG, Sai H,
Tobias J, et al: c-Myc is an important direct target of Notch1 in
T-cell acute lymphoblastic leukemia/lymphoma. Gene Dev.
20:2096–2109. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pear WS, Aster JC, Scott ML, Hasserjian
RP, Soffer B, Sklar J and Baltimore D: Exclusive development of T
cell neoplasms in mice transplanted with bone marrow expressing
activated Notch alleles. J Exp Med. 183:2283–2291. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Klinakis A, Szabolcs M, Politi K, Kiaris
H, Artavanis-Tsakonas S and Efstratiadis A: Myc is a Notch1
transcriptional target and a requisite for Notch1-induced mammary
tumorigenesis in mice. Pro Natl Acad Sci USA. 103:9262–9267. 2006.
View Article : Google Scholar
|
|
6
|
Rizzo P, Osipo C, Foreman K, Golde T,
Osborne B and Miele L: Rational targeting of Notch signaling in
cancer. Oncogene. 27:5124–5131. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Roy M, Pear WS and Aster JC: The
multifaceted role of Notch in cancer. Curr Opin Genet Dev.
17:52–59. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sharma VM, Calvo JA, Draheim KM,
Cunningham LA, Hermance N, Beverly L, Krishnamoorthy V, Bhasin M,
Capobianco AJ and Kelliher MA: Notch1 contributes to mouse T-cell
leukemia by directly inducing the expression of c-Myc. Mol Cell
Biol. 26:8022–8031. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kong R, Feng J, Ma Y, Zhou B, Li S, Zhang
W, Jiang J, Zhang J, Qiao Z, Zhang T, et al: Silencing NACK by
siRNA inhibits tumorigenesis in non-small cell lung cancer via
targeting Notch1 signaling pathway. Oncol Rep. 35:2306–2314. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Y, Wang J, Li C and Ke XY: Contribution
of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting
therapy. Leuk Lymphoma. 53:2015–2023. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang Z, Qi Y, Lu C, Zhang J, Luo R and
Kang S: Small interfering RNA (siRNA)-mediated knockdown of Notch1
suppresses tumor growth and enhances the effect of IL-2
immunotherapy in malignant melanoma. J BUON. 20:1553–1564.
2015.PubMed/NCBI
|
|
12
|
Woo SH, Parker MH, Ploypradith P, Northrop
J and Posner GH: Direct conversion of pyranose anomeric OH→F→R in
the artemisinin family of antimalarial trioxanes. Tetrahedron Lett.
39:1533–1536. 1998. View Article : Google Scholar
|
|
13
|
Wang Q, Wu S, Zhao X, Zhao C, Zhao H and
Huo L: Mechanisms of Dihydroartemisinin and
Dihydroartemisinin/holotransferrin cytotoxicity in T-cell lymphoma
cells. PLoS One. 10:e01373312015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dong F, Tian H, Yan S, Li L, Dong X, Wang
F, Li J, Li C, Cao Z, Liu X and Liu J: Dihydroartemisinin inhibits
endothelial cell proliferation through the suppression of the ERK
signaling pathway. Int J Mol Med. 35:1381–1387. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang CZ, Pan Y, Cao Y, Lai PB, Liu L,
Chen GG and Yun J: Histone deacetylase inhibitors facilitate
dihydroartemisinin-induced apoptosis in liver cancer in vitro and
in vivo. PLoS One. 7:1726–1729. 2012.
|
|
16
|
Wang SJ, Gao Y, Chen H, Kong R, Jiang HC,
Pan SH, Xue DB, Bai XW and Sun B: Dihydroartemisinin inactivates
NF-kappa B and potentiates the anti-tumor effect of gemcitabine on
pancreatic cancer both in vitro and in vivo. Cancer Lett.
293:99–108. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kamstrup MR, Biskup E, Gjerdrum LM,
Ralfkiaer E, Niazi O and Gniadecki R: The importance of Notch
signaling in peripheral T-cell lymphomas. Leuk lymph. 55:639–644.
2014. View Article : Google Scholar
|
|
19
|
Pear WS and Aster JC: T cell acute
lymphoblastic leukemia/lymphoma: A human cancer commonly associated
with aberrant NOTCH1 signaling. Curr Opin Hematol. 11:426–433.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu JJ, Meng LH, Shankavaram UT, Zhu CH,
Tong LJ, Chen G, Lin LP, Weinstein JN and Ding J:
Dihydroartemisinin accelerates c-MYC oncoprotein degradation and
induces apoptosis in c-MYC-overexpressing tumor cells. Biochem
Pharmaco. 80:22–30. 2010. View Article : Google Scholar
|
|
21
|
Sun HW, Wu C, Tan HY and Wang QS:
Combination DLL4 with Jagged1-siRNA can enhance inhibition of the
proliferation and invasiveness activity of human gastric carcinoma
by Notch1/VEGF pathway. Hepatogastroenterology. 59:924–929.
2012.PubMed/NCBI
|
|
22
|
Bin Hafeez B, Mustafa Adhami V, Asim M,
Siddiqui IA, Bhat KM, Zhong W, Saleem M, Din M, Setaluri V and
Mukhtar H: Targeted knockdown of Notch1 inhibits invasion of human
prostate cancer cells concomitant with inhibition of matrix
metalloproteinase-9 and urokinase plasminogen activator. Clin
Cancer Res. 15:452–459. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao X, Zhong H, Wang R, Liu D, Waxman S,
Zhao L and Jing Y: Dihydroartemisinin and its derivative induce
apoptosis in acute myeloid leukemia through Noxa-mediated pathway
requiring iron and endoperoxide moiety. Oncotarget. 6:5582–5596.
2015.PubMed/NCBI
|
|
24
|
He Q, Shi JX, Shen XL, An J, Sun H, Wang
L, Hu YJ, Sun Q, Fu LC, Sheikh MS and Huang Y: Dihydroartemisinin
upregulates death receptor 5 expression and cooperates with TRAIL
to induce apoptosis in human prostate cancer cells. Cancer Biol
Ther. 9:819–824. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cabello CM, Lamore SD, Bair WB III, Qiao
S, Azimian S, Lesson JL and Wondrak GT: The redox antimalarial
dihydroartemisinin targets human metastatic melanoma cells but not
primary melanocytes with induction of NOXA-dependent apoptosis.
Invest New Drug. 30:1289–1301. 2012. View Article : Google Scholar
|
|
26
|
Liao K, Li J and Wang ZL:
Dihydroartemisinin inhibits cell proliferation via
AKT/GSK3β/cyclinD1 pathway and induces apoptosis in A549 lung
cancer cells. Int J Clin Exp Patho. 7:8684–8691. 2014.
|
|
27
|
Tong Y, Liu Y, Zheng H, Zheng L, Liu W, Wu
J, Ou R, Zhang G, Li F, Hu M, et al: Artemisinin and its
derivatives can significantly inhibit lung tumorigenesis and tumor
metastasis through Wnt/β-catenin signaling. Oncotarget.
7:31413–31428. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Handrick R, Ontikatze T, Bauer KD, Freier
F, Rübel A, Dürig J, Belka C and Jendrossek V: Dihydroartemisinin
induces apoptosis by a Bak-dependent intrinsic pathway. Mol Cancer
Ther. 9:2497–2510. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Han P, Luan Y, Liu Y, Yu Z, Li J, Sun Z,
Chen G and Cui B: Small interfering RNA targeting Rac1 sensitizes
colon cancer to dihydroartemisinin-induced cell cycle arrest and
inhibited cell migration by suppressing NFκB activity. Mol Cell
Biochem. 379:171–180. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim MJ, Park JS, Lee SJ, Jang J, Park JS,
Back SH, Bahn G, Park JH, Kang YM, Kim SH, et al: Notch1 targeting
siRNA delivery nanoparticles for rheumatoid arthritis therapy. J
Control Release. 216:140–148. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tezgel AÖ, Gonzalez-Perez G, Telfer JC,
Osborne BA, Minter LM and Tew GN: Novel protein transduction domain
mimics as nonviral delivery vectors for siRNA targeting NOTCH1 in
primary human T cells. Mol Ther. 21:201–209. 2013. View Article : Google Scholar : PubMed/NCBI
|
